Show simple item record

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

dc.contributor.authorVan Allen, Eliezer M.
dc.contributor.authorAmin-Mansour, Ali
dc.contributor.authorTaylor-Weiner, Amaro
dc.contributor.authorRosenberg, Mara
dc.contributor.authorBarletta, Justine A.
dc.contributor.authorGuo, Yanan
dc.contributor.authorSwanson, Scott J.
dc.contributor.authorRuan, Daniel T.
dc.contributor.authorHanna, Glenn J.
dc.contributor.authorHaddad, Robert I.
dc.contributor.authorKwiatkowski, David J.
dc.contributor.authorJänne, Pasi A.
dc.contributor.authorLorch, Jochen H.
dc.contributor.authorWagle, Nikhil
dc.contributor.authorGrabiner, Brian
dc.contributor.authorGray, Nathanael S
dc.contributor.authorGetz, Gad Asher
dc.contributor.authorCarter, Scott
dc.contributor.authorSabatini, David
dc.contributor.authorGarraway, Levi A.
dc.date.accessioned2017-04-21T19:26:46Z
dc.date.available2017-04-21T19:26:46Z
dc.date.issued2014-10
dc.identifier.issn0028-4793
dc.identifier.issn1533-4406
dc.identifier.urihttp://hdl.handle.net/1721.1/108362
dc.description.abstractEverolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain undefined. Resistance developed in a patient with metastatic anaplastic thyroid carcinoma after an extraordinary 18-month response. Whole-exome sequencing of pretreatment and drug-resistant tumors revealed a nonsense mutation in TSC2, a negative regulator of mTOR, suggesting a mechanism for exquisite sensitivity to everolimus. The resistant tumor also harbored a mutation in MTOR that confers resistance to allosteric mTOR inhibition. The mutation remains sensitive to mTOR kinase inhibitors.en_US
dc.language.isoen_US
dc.publisherNew England Journal of Medicineen_US
dc.relation.isversionofhttp://dx.doi.org/10.1056/NEJMoa1403352en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourceNew England Journal of Medicineen_US
dc.titleResponse and Acquired Resistance to Everolimus in Anaplastic Thyroid Canceren_US
dc.typeArticleen_US
dc.identifier.citationWagle, Nikhil; Grabiner, Brian C.; Van Allen, Eliezer M.; Amin-Mansour, Ali; Taylor-Weiner, Amaro; Rosenberg, Mara; Gray, Nathanael et al. “Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer.” New England Journal of Medicine 371, no. 15 (October 2014): 1426–1433. © New England Journal of Medicineen_US
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Medical Engineering & Scienceen_US
dc.contributor.departmentBroad Institute of MIT and Harvarden_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.mitauthorWagle, Nikhil
dc.contributor.mitauthorGrabiner, Brian
dc.contributor.mitauthorGray, Nathanael S
dc.contributor.mitauthorGetz, Gad Asher
dc.contributor.mitauthorCarter, Scott
dc.contributor.mitauthorSabatini, David
dc.contributor.mitauthorGarraway, Levi
dc.relation.journalNew England Journal of Medicineen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsWagle, Nikhil; Grabiner, Brian C.; Van Allen, Eliezer M.; Amin-Mansour, Ali; Taylor-Weiner, Amaro; Rosenberg, Mara; Gray, Nathanael; Barletta, Justine A.; Guo, Yanan; Swanson, Scott J.; Ruan, Daniel T.; Hanna, Glenn J.; Haddad, Robert I.; Getz, Gad; Kwiatkowski, David J.; Carter, Scott L.; Sabatini, David M.; Jänne, Pasi A.; Garraway, Levi A.; Lorch, Jochen H.en_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0002-1446-7256
mit.licensePUBLISHER_POLICYen_US
mit.metadata.statusComplete


Files in this item

Thumbnail
Name:
Sabatini_Response and.pdf
Size:
1004.Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record